Loading...
Please wait, while we are loading the content...
Similar Documents
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
| Content Provider | Semantic Scholar |
|---|---|
| Author | Rimassa, Lorenza Abbadessa, Giovanni Personeni, Nicola Porta, Camillo Borbath, Ivan Daniele, Bruno Salvagni, Stefania Tabernero, José Díaz Vlierberghe, Hans R. Van Trojan, Jörg Toni, Enrico N. De Weiss, Alan Miles, Steven D. Gasbarrini, Antonio Lencioni, Monica Simonelli, Matteo Wang, Yunxia Shuster, Dale E. Schwartz, Brian E. Santoro, A. Guijarro |
| Copyright Year | 2016 |
| Abstract | ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC.Aim of this research was to study the prognostic and predictive value of tumor (MET, the receptor tyrosine kinase encoded by the homonymous MNNG-HOS transforming gene) and circulating (MET, hepatocyte growth factor [HGF], alpha-fetoprotein [AFP], vascular endothelial growth factor [VEGF]) biomarkers in second-line HCC. Tumor MET-High status was centrally assessed by immunohistochemistry. Circulating biomarkers were centrally analyzed on serum samples collected at baseline and every 4-8 weeks, using medians as cut-off to determine High/Low status. Tumor MET, tested in 77 patients, was more frequently High after (82%) versus before (40%) sorafenib. A significant interaction (p = 0.04) between tivantinib and baseline tumor MET in terms of survival was observed. Baseline circulating MET and HGF (102 patients) High status correlated with shorter survival (HR 0.61, p = 0.03, and HR 0.60, p = 0.02, respectively), while the association between AFP (104 patients) or VEGF (103 patients) status and survival was non-significant. CONCLUSIONS Tumor MET levels were higher in patients treated with sorafenib. Circulating biomarkers such as MET and HGF may be prognostic in second-line HCC. These results need to be confirmed in larger randomized clinical trials. |
| Starting Page | 72622 |
| Ending Page | 72633 |
| Page Count | 12 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.oncotarget.com/index.php?journal=oncotarget&op=download&page=article&path%5B%5D=11621&path%5B%5D=36798 |
| PubMed reference number | 27579536 |
| Alternate Webpage(s) | https://doi.org/10.18632/oncotarget.11621 |
| DOI | 10.18632/oncotarget.11621 |
| Journal | Oncotarget |
| Volume Number | 7 |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Adrenergic alpha-Agonists Biological Markers Fetal Proteins Hepatocyte Growth Factor Large Liver carcinoma Methylnitronitrosoguanidine Neoplasms Patients Protein Tyrosine Kinase Receptor Protein-Tyrosine Kinases alpha-Fetoproteins sorafenib tivantinib |
| Content Type | Text |
| Resource Type | Article |
